Krish Patel
Director of Lymphoma Research
Sarah Cannon Research Institute · Nashville, United States
Key investigator in the development of pirtobrutinib (non-covalent BTK inhibitor) for MCL, including the pivotal BRUIN trial.
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.
Cancer · Apr 15, 2026
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.
Blood · Mar 19, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.
Current medical research and opinion · Dec 1, 2025
Converging approaches in the frontline treatment of mantle cell lymphoma.
Clinical advances in hematology & oncology : H&O · Nov 1, 2025
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial.
Haematologica · Mar 1, 2025
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Haematologica · Jan 1, 2025
In-vivo pharmacokinetic study of ibrutinib-loaded nanostructured lipid carriers in rat plasma by sensitive spectrofluorimetric method using harmonized approach of quality by design and white analytical chemistry.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · Nov 15, 2024
Clinical Warburg Effect in a Patient With Mantle Cell Lymphoma: A Case Report.
Cureus · Apr 1, 2024
Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy.
Hematological oncology · Jan 1, 2024